Working with patients, we are developing proven applications that deliver precision safety and monitoring techniques in the clinical trial setting. Our precision medicine capabilities are rapidly expanding, enabling the classification of cancer tumours according to their genetic make-up, using tumour and blood biomarkers, and selection of a therapy to target specific individual tumour molecular changes.
We want to significantly improve the application of clinical trial informatics to better identify the right cancer treatment for individual patients.
This will make personalised medicine a reality – delivering the right treatment to the right patient at the right time.
digital ECMT is harnessing digital technology and solutions that will initially be used within the Experimental Cancer Medicine Team, (ECMT) for early cancer trials at The Christie NHS Foundation Trust.
Our work will drive change for patient benefit. We also want our applications to enable more patients to take part in clinical trials, through precision monitoring of safety and efficacy. The ability to provide improved targeted monitoring will enable trial organisers to expand the inclusion criteria, giving a broader range of patients the opportunity to participate.